Donald R Latner1, Amy Parker Fiebelkorn1, Marcia McGrew1, Nobia J Williams1, Laura A Coleman2,3, Huong Q McLean2, Steven Rubin4, Carole J Hickman1. 1. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Foundation, Marshfield, Wisconsin. 3. Novartis Institutes for Biomedical Research, Cambridge, Massachusetts. 4. Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland.
Abstract
BACKGROUND: Recent mumps outbreaks among 2-dose measles mumps rubella (MMR) vaccine recipients have raised questions regarding the potential benefits of a third dose of vaccine (MMR3). If MMR3 provides a sustained elevation in mumps antibody, it may be beneficial for certain at-risk groups or as an outbreak control measure. METHODS: Sera were collected immediately prior to MMR3 and at 1 month and 1 year post-MMR3 from 656 healthy adults aged 18-28 years in a nonoutbreak setting. Immunoglobulin G (IgG) was measured by enzyme-linked immunosorbent assay (ELISA) using whole mumps virus (commercial ELISA), hemagglutinin (HN; major neutralizing target), and nucleoprotein (NP; immunodominant) antigens. ELISA measurements were compared with in vitro plaque reduction neutralization (PRN) titers, and baseline antibody was compared with post-MMR3 levels. RESULTS: There were modest but statistically significant (P < .05) increases in mumps antibody at 1 month post-MMR3 by all 3 ELISA methods and by PRN titer. At 1 year post-MMR3, mumps antibody declined toward baseline but remained elevated (P < .05). The correlation between PRN titers and ELISA measurements was poor (r2 = .49), although sera with the highest amount of HN IgG also had the highest PRN titers. CONCLUSIONS: Individuals with the lowest baseline PRN titers had the largest increase in frequency of samples that became positive for HN and NP by ELISA. A third dose of MMR may benefit certain individuals with a low level of mumps virus-neutralizing antibody, especially in the context of an outbreak or other high-risk setting. Additionally, poor correlation among serologic tests does not allow effective prediction of PRN titer by ELISA.
BACKGROUND: Recent mumps outbreaks among 2-dose measles mumps rubella (MMR) vaccine recipients have raised questions regarding the potential benefits of a third dose of vaccine (MMR3). If MMR3 provides a sustained elevation in mumps antibody, it may be beneficial for certain at-risk groups or as an outbreak control measure. METHODS: Sera were collected immediately prior to MMR3 and at 1 month and 1 year post-MMR3 from 656 healthy adults aged 18-28 years in a nonoutbreak setting. Immunoglobulin G (IgG) was measured by enzyme-linked immunosorbent assay (ELISA) using whole mumps virus (commercial ELISA), hemagglutinin (HN; major neutralizing target), and nucleoprotein (NP; immunodominant) antigens. ELISA measurements were compared with in vitro plaque reduction neutralization (PRN) titers, and baseline antibody was compared with post-MMR3 levels. RESULTS: There were modest but statistically significant (P < .05) increases in mumps antibody at 1 month post-MMR3 by all 3 ELISA methods and by PRN titer. At 1 year post-MMR3, mumps antibody declined toward baseline but remained elevated (P < .05). The correlation between PRN titers and ELISA measurements was poor (r2 = .49), although sera with the highest amount of HN IgG also had the highest PRN titers. CONCLUSIONS: Individuals with the lowest baseline PRN titers had the largest increase in frequency of samples that became positive for HN and NP by ELISA. A third dose of MMR may benefit certain individuals with a low level of mumps virus-neutralizing antibody, especially in the context of an outbreak or other high-risk setting. Additionally, poor correlation among serologic tests does not allow effective prediction of PRN titer by ELISA.
Authors: J Whelan; R van Binnendijk; K Greenland; E Fanoy; M Khargi; K Yap; H Boot; N Veltman; C Swaan; A van der Bij; H de Melker; S Hahné Journal: Euro Surveill Date: 2010-04-29
Authors: Erlend T Aasheim; Thomas Inns; Amy Trindall; Lynsey Emmett; Kevin E Brown; Chris J Williams; Mark Reacher Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: J S Rota; J C Turner; M K Yost-Daljev; M Freeman; D M Toney; E Meisel; N Williams; S B Sowers; L Lowe; P A Rota; L A Nicolai; L Peake; W J Bellini Journal: J Med Virol Date: 2009-10 Impact factor: 2.327
Authors: Margaret M Cortese; Hannah T Jordan; Aaron T Curns; Patricia A Quinlan; Kim A Ens; Patricia M Denning; Gustavo H Dayan Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079
Authors: Albert E Barskey; Cynthia Schulte; Jennifer B Rosen; Elizabeth F Handschur; Elizabeth Rausch-Phung; Margaret K Doll; Kisha P Cummings; E Oscar Alleyne; Patricia High; Jacqueline Lawler; Andria Apostolou; Debra Blog; Christopher M Zimmerman; Barbara Montana; Rafael Harpaz; Carole J Hickman; Paul A Rota; Jennifer S Rota; William J Bellini; Kathleen M Gallagher Journal: N Engl J Med Date: 2012-11-01 Impact factor: 91.245
Authors: Kelsey Briggs; Cara Kirby; Ashley C Beavis; James Zengel; Preetish Patil; Christian Sauder; Biao He Journal: J Virol Date: 2022-04-07 Impact factor: 6.549
Authors: Mohammed Ata Ur Rasheed; Carole J Hickman; Marcia McGrew; Sun Bae Sowers; Sara Mercader; Amy Hopkins; Vickie Grimes; Tianwei Yu; Jens Wrammert; Mark J Mulligan; William J Bellini; Paul A Rota; Walter A Orenstein; Rafi Ahmed; Srilatha Edupuganti Journal: Proc Natl Acad Sci U S A Date: 2019-09-03 Impact factor: 12.779
Authors: Jelle de Wit; Maarten E Emmelot; Martien C M Poelen; Josien Lanfermeijer; Wanda G H Han; Cécile A C M van Els; Patricia Kaaijk Journal: J Virol Date: 2019-03-05 Impact factor: 5.103
Authors: Patricia Kaaijk; Alienke J Wijmenga-Monsuur; Hinke I Ten Hulscher; Jeroen Kerkhof; Gaby Smits; Mioara Alina Nicolaie; Marianne A van Houten; Rob S van Binnendijk Journal: Vaccines (Basel) Date: 2022-01-17